.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Queensland Health
Accenture
Johnson and Johnson
Cipla
UBS
Federal Trade Commission
Harvard Business School
Julphar
Merck

Generated: December 15, 2017

DrugPatentWatch Database Preview

ERY-TAB Drug Profile

« Back to Dashboard

When do Ery-tab patents expire, and what generic alternatives are available?

Ery-tab is a drug marketed by Arbor Pharms Llc and is included in one NDA.

The generic ingredient in ERY-TAB is erythromycin. There are ninety-nine drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the erythromycin profile page.
Drug patent expirations by year for ERY-TAB

Pharmacology for ERY-TAB

Medical Subject Heading (MeSH) Categories for ERY-TAB

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Arbor Pharms LlcERY-TABerythromycinTABLET, DELAYED RELEASE;ORAL062298-001Approved Prior to Jan 1, 1982RXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Arbor Pharms LlcERY-TABerythromycinTABLET, DELAYED RELEASE;ORAL062298-003Mar 29, 1982RXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Arbor Pharms LlcERY-TABerythromycinTABLET, DELAYED RELEASE;ORAL062298-002Approved Prior to Jan 1, 1982RXNoYes► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
Covington
Citi
Fish and Richardson
Julphar
Cipla
Johnson and Johnson
McKinsey
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot